NDA 021503 · Agouron Pharms
Viracept
Nelfinavir Mesylate · Oral
Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Apr 30, 2003
Approved uses
2
Original approval plus efficacy supplements
Registered trials
144
24 Phase 3, 3 recruiting
FAERS reports
2,091
1,922 serious, 110 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 11, 2025.
VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. VIRACEPT is a protease inhibitor indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. ( 1 )
Mechanism: Nelfinavir is an inhibitor of the HIV-1 protease [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 19, 2004 Supplement 1 · Efficacy · priority review LabelReviewLetter
- Apr 30, 2003 Original approval · Type 3 - New Dosage Form LetterLabelReview
1 products under this application
- VIRACEPT · NELFINAVIR MESYLATE EQ 625MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nelfinavir" as an intervention, any sponsor and status, largest first.
- Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV TransmissionPivotal-lookingCompleted
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00099359 · 1,735 participants · Start Feb 2004 · Primary completion Feb 2011
Drug: Zidovudine; Nevirapine (NVP) and 2 more · For: Disease Transmission, Vertical; Vertical Human Immunodeficiency Virus Transmission; HIV Infections
Sites: Long Beach, California; Gainesville, Florida; Jacksonville, Florida · 17 sites in all
- A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000922 · 1,710 participants · Primary completion Jan 2003
Drug: Indinavir sulfate; Abacavir sulfate and 6 more · For: HIV Infections
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 17 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000859 · 1,300 participants
Drug: Indinavir sulfate; Ritonavir and 1 more · For: HIV Infections
Sites: San Francisco, California; Denver, Colorado; Washington D.C., District of Columbia · 44 sites in all
- A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV InfectionCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000919 · 900 participants
Drug: Indinavir sulfate; Lamivudine/Zidovudine and 10 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Menlo Park, California · 80 sites in all
- A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected PatientsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00002378 · 825 participants
Drug: Ritonavir; Nelfinavir mesylate and 5 more · For: HIV Infections
Sites: Anniston, Alabama; Phoenix, Arizona; Tucson, Arizona · 102 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000914 · 800 participants
Drug: Indinavir sulfate; Ritonavir and 2 more · For: HIV Infections
Sites: San Francisco, California; Denver, Colorado; Washington D.C., District of Columbia · 15 sites in all
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
- Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)Pivotal-lookingStatus unknown
Agouron PharmaceuticalsIndustry
NCT00005002 · 688 participants
Drug: Lamivudine/Zidovudine; HIV-1 Immunogen and 1 more · For: HIV Infections
Sites: San Diego, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug exposure during pregnancy414
- pain243
- anxiety236
- emotional distress236
- anhedonia210
- foetal exposure during pregnancy203
- chronic kidney disease140
- osteoporosis137
- anaemia120
- bone density decreased115
- premature baby115
- depression110
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 194 |
| 2005 | 209 |
| 2006 | 199 |
| 2007 | 161 |
| 2008 | 83 |
| 2009 | 93 |
| 2010 | 209 |
| 2011 | 101 |
| 2012 | 51 |
| 2013 | 29 |
| 2014 | 31 |
| 2015 | 95 |
| 2016 | 91 |
| 2017 | 29 |
| 2018 | 46 |
| 2019 | 130 |
| 2020 | 145 |
| 2021 | 105 |
| 2022 | 42 |
| 2023 | 19 |
| 2024 | 1 |
| 2025 | 8 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Viracept (Nelfinavir Mesylate)
2024 spending
$705K
Beneficiaries
64
515 claims
Per beneficiary
$11,019
$9.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,431,046 |
| 2021 | $1,279,965 |
| 2022 | $1,144,770 |
| 2023 | $909,064 |
| 2024 | $705,212 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2.
Xu Z, Shi D, Han JB, et al. · Signal Transduct Target Ther 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.
Mukherjee S, Qi C, Shaw R, et al. · Eur J Cancer 2024 · Randomized Controlled Trial, Multicenter Study
- HIV-protease inhibitors alter retinoic acid synthesis.
Toma E, Devost D, Chow Lan N, et al. · AIDS 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
- Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Driessen C, Müller R, Novak U, et al. · Blood 2018 · Clinical Trial, Phase II, Letter
- Hepatotoxicity and nelfinavir: a meta-analysis.
Bruno R, Sacchi P, Maiocchi L, et al. · Clin Gastroenterol Hepatol 2005 · Meta-Analysis, Review
- CD36 deficiency induced by antiretroviral therapy.
Serghides L, Nathoo S, Walmsley S, et al. · AIDS 2002 · Clinical Trial, Randomized Controlled Trial
Sponsor: Agouron Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.